Genmab A-S News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.04.25	Genmab A/S Share Capital Reduction (GlobeNewswire)
09.04.25	What Analysts Are Saying About Genmab Stock (Benzinga)
07.04.25	Transactions In Connection with Share Buy-back Program (GlobeNewswire)
01.04.25	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
31.03.25	TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer (GlobeNewswire)
31.03.25	Transactions in connection with share buy-back program (GlobeNewswire)
27.03.25	Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer (Benzinga)
27.03.25	TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy (GlobeNewswire)
25.03.25	Genmab Announces Initiation of Share Buy-Back Program (GlobeNewswire)
22.03.25	Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. (GlobeNewswire)
17.03.25	Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer (GlobeNewswire)
12.03.25	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
12.03.25	Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
11.03.25	Breaking Down Genmab: 4 Analysts Share Their Views (Benzinga)
10.03.25	Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 (GlobeNewswire)
04.03.25	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
28.02.25	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (GlobeNewswire)
28.02.25	Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab (GlobeNewswire)
25.02.25	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
20.02.25	EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma (GlobeNewswire)
19.02.25	Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
13.02.25	Notice to Convene the Annual General Meeting of Genmab A/S (GlobeNewswire)
12.02.25	Genmab Files Annual Report with the U.S. Securities and Exchange Commission (GlobeNewswire)
12.02.25	Genmab Publishes 2024 Annual Report (GlobeNewswire)
11.02.25	Ausblick: Genmab A-S stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
28.01.25	Erste Schätzungen: Genmab A-S verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
23.01.25	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
22.01.25	Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024 (GlobeNewswire)
03.01.25	Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
11.12.24	Genmab to Hold 2024 R&D Update and ASH Data Review Meeting (GlobeNewswire)
09.12.24	Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (GlobeNewswire)
08.12.24	Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukem (GlobeNewswire)
08.12.24	Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (GlobeNewswire)
03.12.24	Capital Increase in Genmab as a Result of Employee Warrant Exercise (GlobeNewswire)
03.12.24	Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons (GlobeNewswire)
25.11.24	Genmab to Present at Citi’s Global Healthcare Conference (GlobeNewswire)
21.11.24	Grant of Restricted Stock Units and Warrants to Employees in Genmab (GlobeNewswire)
08.11.24	A Closer Look at 10 Analyst Recommendations For Genmab (Benzinga)
06.11.24	Genmab Announces Financial Results for the First Nine Months of 2024 (GlobeNewswire)
05.11.24	Genmab to Present at Jefferies London Healthcare Conference (GlobeNewswire)
05.11.24	Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
05.11.24	Ausblick: Genmab A-S präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
22.10.24	Erste Schätzungen: Genmab A-S legt Zahlen zum jüngsten Quartal vor (finanzen.net)
16.10.24	12 Analysts Have This To Say About Genmab (Benzinga)
15.10.24	Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	86.09	1.63 %	K V
Geberit	538.00	1.62 %	K V
Givaudan	3’714.00	1.25 %	K V
Swisscom	515.50	1.08 %	K V
Nestle	84.98	0.81 %	K V
Swiss Re	138.05	-0.83 %	K V
Sonova Hldg	231.60	-1.28 %	K V
Logitech Intl	56.94	-2.00 %	K V
ABB	40.27	-2.21 %	K V
Zurich Insur Gr	529.20	-5.30 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Genmab A-S Aktie VALOR 1129757 / ISIN DK0010272202

Nachrichten zu Genmab A-S

Aktien Top/Flop

Genmab A-S Peer Group Nachrichten

Meistgelesene Nachrichten